Stealthy BioTrace Medical brings in $3.4 million in a hoped-for $3.5 million round for the heart pacing technology it's developing.
BioTrace Medical is closing in on its $3.5 million goal, having raised $3.4 million in a funding round, according to a regulatory filing.
BioTrace, which is backed by early-stage medtech angel Xandex Investments, is developing a temporary cardiac pacing device to treat reversible symptomatic bradycardia.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/NrNUh8
Cap comentari:
Publica un comentari a l'entrada